Palvella Therapeutics, Inc. Revenue Not from Contract with Customer
Palvella Therapeutics, Inc. (PVLA) reported Revenue Not from Contract with Customer of -$192.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RevenueNotFromContractWithCustomer · last filed 2022-05-11
- Palvella Therapeutics, Inc. revenue not from contract with customer for the quarter ending 2022-03-31 was -$192.00K, a 125.03% decline year-over-year.
- Palvella Therapeutics, Inc. revenue not from contract with customer for the quarter ending 2021-12-31 was $692.00K, a 92.76% increase year-over-year.
- Palvella Therapeutics, Inc. revenue not from contract with customer for the quarter ending 2021-09-30 was $1.27M, a 252.91% increase year-over-year.
- Palvella Therapeutics, Inc. revenue not from contract with customer for the quarter ending 2021-06-30 was $745.00K, a 135.76% increase year-over-year.
- Palvella Therapeutics, Inc. revenue not from contract with customer for fiscal 2021 was $3.48M, a 35.74% decline from fiscal 2020.
- Palvella Therapeutics, Inc. revenue not from contract with customer for fiscal 2020 was $5.41M, a 61.92% decline from fiscal 2019.
- Palvella Therapeutics, Inc. revenue not from contract with customer for fiscal 2019 was $14.21M.
| Period end | Revenue Not from Contract with Customer 3 month | Revenue Not from Contract with Customer 6 month | Revenue Not from Contract with Customer 9 month | Revenue Not from Contract with Customer 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$192.00K 10-Q · filed 2022-05-11 | $500.00K derived: sum of 2 quarters · filed 2022-05-11 | $1.77M derived: sum of 3 quarters · filed 2022-05-11 | $2.52M derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-12-31 | $692.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $1.97M derived: sum of 2 quarters · filed 2022-03-02 | $2.71M derived: sum of 3 quarters · filed 2022-03-02 | $3.48M 10-K · filed 2022-03-02 |
| 2021-09-30 | $1.27M 10-Q · filed 2021-11-02 | $2.02M derived: sum of 2 quarters · filed 2021-11-02 | $2.79M 10-Q · filed 2021-11-02 | $3.15M derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-06-30 | $745.00K 10-Q · filed 2021-08-05 | $1.51M 10-Q · filed 2021-08-05 | $1.87M derived: sum of 3 quarters · filed 2022-05-11 | $2.23M derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-03-31 | $767.00K 10-Q · filed 2022-05-11 | $1.13M derived: sum of 2 quarters · filed 2022-05-11 | $1.49M derived: sum of 3 quarters · filed 2022-05-11 | $1.80M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $359.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $720.00K derived: sum of 2 quarters · filed 2022-03-02 | $1.04M derived: sum of 3 quarters · filed 2022-03-02 | $5.41M 10-K · filed 2022-03-02 |
| 2020-09-30 | $361.00K 10-Q · filed 2021-11-02 | $677.00K derived: sum of 2 quarters · filed 2021-11-02 | $5.05M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $316.00K 10-Q · filed 2021-08-05 | $4.69M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $4.38M 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $14.21M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |